Earnings Per Share

6 Months Ended

Jun. 30, 2012

Earnings Per Share

Earnings Per Share

4.    Earnings Per Share

	Three-Month Periods Ended				Six-Month Periods Ended
	June 30,				June 30,
(Amounts in thousands, except per share)	2012		2011		2012		2011
Net income attributable to Celgene	$	367,373	$	279,398	$	768,910	$	534,988
Weighted-average shares:
Basic	436,703		462,625		437,526		464,300
Effect of dilutive securities:
Options, restricted stock units, warrants and other	8,676		7,337		9,566		6,658
Diluted	445,379		469,962		447,092		470,958
Net income per share:
Basic	$	0.84	$	0.60	$	1.76	$	1.15
Diluted	$	0.82	$	0.59	$	1.72	$	1.14

The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 10,355,082 and 21,840,944 shares for the three-month periods ended June 30, 2012 and 2011, respectively.  The total number of potential common shares excluded for the six-month periods ended June 30, 2012 and 2011 was 8,477,044 and 25,951,468, respectively.

Our Board of Directors has approved common share repurchases  of up to an aggregate of $6.5 billion of our common stock.  As of June 30, 2012, an aggregate of 56,241,949 shares of common stock were repurchased under the program, including 8,062,564 shares of common stock repurchased during the three-month period ended June 30, 2012.  As of June 30, 2012 we had a remaining open-ended authorization of $3.161 billion.